Product

Hikma receives FDA approval for Acyclovir Injection

London, 9 March 2016 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces that its abbreviated new drug application (“ANDA”) for Acyclovir Injection USP, 500mg/vial and 1 gm/vial, single dose vials, has been approved by the U.S. Food and Drug Administration (“FDA”).

Acylcovir Injection is used to treat initial and recurrent herpes simplex, shingles (varicella zoster) infection, genital herpes and herpes simplex encephalitis. According to IMS Health, sales of Acyclovir Injection in the US market were approximately $14.7 million for the 12 months ending January 2016.